Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.040 Biomarker phenotype BEFREE A total of 61 tumours (benign and malignant) were deemed suitable for the study. p16INK4 staining yielded three (4.9 per cent) positive samples: one small cell carcinoma, one squamous cell carcinoma and one poorly differentiated carcinoma. 26190415 2015
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.040 AlteredExpression phenotype BEFREE The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). 15818729 2005
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.040 AlteredExpression phenotype BEFREE The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < 0.05). 11819820 2001
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.040 AlteredExpression phenotype BEFREE A clinicopathologic survey indicated that a low or no expression of p16(INK4) was associated with poorly differentiated carcinoma (p = 0.0133), but the level of expression did not correlate with other parameters including patients' prognosis or with the expression of the pRb protein. 10705239 2000
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation phenotype BEFREE NGS revealed a BRAF p.K601E mutation in both the clear cell papillary carcinoma and poorly differentiated carcinoma and a KRAS p.G12R mutation in the papillary carcinoma, follicular variant. 27387987 2017
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation phenotype BEFREE A single BRAF mutation was found in a poorly differentiated carcinoma with a residual component of a tall cell variant of papillary carcinoma. 19837916 2009
Entrez Id: 673
Gene Symbol: BRAF
BRAF
0.030 GeneticVariation phenotype BEFREE These findings strongly suggest that this case is a poorly differentiated carcinoma that arose from PTC and implies a possible association of BRAF mutation with dedifferentiated phenotype of PTCs. 16786134 2006
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.020 GeneticVariation phenotype BEFREE NGS revealed a BRAF p.K601E mutation in both the clear cell papillary carcinoma and poorly differentiated carcinoma and a KRAS p.G12R mutation in the papillary carcinoma, follicular variant. 27387987 2017
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.020 AlteredExpression phenotype BEFREE In this study, we investigate the correlation among poorly differentiated carcinoma, epithelial to mesenchymal transition (EMT) phenomenon, and expression of NF-kB, Sonic Hedgehog (SHH), K-RAS, and PTX3 in breast cancer in 100 breast biopsies. 26563370 2016
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.020 AlteredExpression phenotype BEFREE Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer. 24025523 2013
Entrez Id: 3342
Gene Symbol: HTC2
HTC2
0.020 Biomarker phenotype BEFREE Genome wide DNA copy number changes were analyzed by microarray CGH in ACC-HGT, four with transformation into moderately differentiated adenocarcinoma (MDA) and two into poorly differentiated carcinoma (PDC), and five solid ACC. 21541734 2011
Entrez Id: 3342
Gene Symbol: HTC2
HTC2
0.020 Biomarker phenotype BEFREE genome-wide DNA copy number changes were analyzed by microarray CGH in ACC-HGT, 4 with transformation into moderately differentiated adenocarcinoma (MDA) and two into poorly differentiated carcinoma (PDC), 5 solid ACC. 20978318 2010
Entrez Id: 115482713
Gene Symbol: H3P10
H3P10
0.020 AlteredExpression phenotype BEFREE The positive rate of P16 protein expression in mucoid carcinoma (10%, 1/10) was significantly lower than that in poorly differentiated carcinoma (51%, 21/41), undifferentiated carcinoma (58%, 15/26) and signet ring cell carcinoma (62%, 10/16) (P<0.05). 15818729 2005
Entrez Id: 115482713
Gene Symbol: H3P10
H3P10
0.020 AlteredExpression phenotype BEFREE The positive rate of p16 protein expression in mucoid carcinoma 10.00% (1/10) was significantly lower than that in poorly differentiated carcinoma 51.22% (21/41), undifferentiated carcinoma 57.69% (15/26) and signet ring cell carcinoma 62.50% (10/16) (P < 0.05). 11819820 2001
Entrez Id: 54474
Gene Symbol: KRT20
KRT20
0.020 Biomarker phenotype BEFREE Additional immunostaining, which demonstrated positivity for CD20 and kappa light chain, as well as detection of the monoclonal rearrangement of the immunoglobulin heavy chain gene, helped to establish the diagnosis of lymphoma and to rule out an initially favored diagnosis of poorly differentiated carcinoma. 11473470 2001
Entrez Id: 7015
Gene Symbol: TERT
TERT
0.010 GeneticVariation phenotype BEFREE In thyroid cancer, high frequency of TERT mutation was observed in poorly differentiated carcinoma. 31669704 2020
Entrez Id: 4267
Gene Symbol: CD99
CD99
0.010 Biomarker phenotype BEFREE Positivity for CD99 and gata3 in the initial biopsy raised the differential diagnosis of Ewing sarcoma and poorly differentiated carcinoma. 31708666 2019
Entrez Id: 2625
Gene Symbol: GATA3
GATA3
0.010 Biomarker phenotype BEFREE Positivity for CD99 and gata3 in the initial biopsy raised the differential diagnosis of Ewing sarcoma and poorly differentiated carcinoma. 31708666 2019
Entrez Id: 5726
Gene Symbol: TAS2R38
TAS2R38
0.010 Biomarker phenotype BEFREE Histology was reviewed, and the patients were divided in the following three groups: poorly differentiated carcinoma [PDTC; group 1 (n = 27)]; papillary thyroid carcinoma with PDA [PTC with PDA; group 2 (n = 27)]; and follicular thyroid carcinoma with PDA [FTC with PDA; group 3 (n = 88)]. 30673845 2019
Entrez Id: 5979
Gene Symbol: RET
RET
0.010 Biomarker phenotype BEFREE Histology was reviewed, and the patients were divided in the following three groups: poorly differentiated carcinoma [PDTC; group 1 (n = 27)]; papillary thyroid carcinoma with PDA [PTC with PDA; group 2 (n = 27)]; and follicular thyroid carcinoma with PDA [FTC with PDA; group 3 (n = 88)]. 30673845 2019
Entrez Id: 2158
Gene Symbol: F9
F9
0.010 Biomarker phenotype BEFREE Histology was reviewed, and the patients were divided in the following three groups: poorly differentiated carcinoma [PDTC; group 1 (n = 27)]; papillary thyroid carcinoma with PDA [PTC with PDA; group 2 (n = 27)]; and follicular thyroid carcinoma with PDA [FTC with PDA; group 3 (n = 88)]. 30673845 2019
Entrez Id: 3642
Gene Symbol: INSM1
INSM1
0.010 AlteredExpression phenotype BEFREE Histopathological re-examination of a recurrent tumor revealed poorly differentiated carcinoma with insulinoma-associated protein 1 (INSM1) expression, which remained ALK-positive. 30900377 2019
Entrez Id: 5727
Gene Symbol: PTCH1
PTCH1
0.010 Biomarker phenotype BEFREE Histology was reviewed, and the patients were divided in the following three groups: poorly differentiated carcinoma [PDTC; group 1 (n = 27)]; papillary thyroid carcinoma with PDA [PTC with PDA; group 2 (n = 27)]; and follicular thyroid carcinoma with PDA [FTC with PDA; group 3 (n = 88)]. 30673845 2019
Entrez Id: 8030
Gene Symbol: CCDC6
CCDC6
0.010 Biomarker phenotype BEFREE Histology was reviewed, and the patients were divided in the following three groups: poorly differentiated carcinoma [PDTC; group 1 (n = 27)]; papillary thyroid carcinoma with PDA [PTC with PDA; group 2 (n = 27)]; and follicular thyroid carcinoma with PDA [FTC with PDA; group 3 (n = 88)]. 30673845 2019
Entrez Id: 23314
Gene Symbol: SATB2
SATB2
0.010 Biomarker phenotype BEFREE SATB2 staining was seen in 1/1 metastatic appendiceal poorly differentiated carcinoma with signet ring cells (5% cells), 1/3 MKTs of bladder origin (60% cells), 0/2 MKTs of pulmonary origin, and 1/5 MKTs of breast origin (10% cells). 28914716 2018